
Sepul Bio start eerste dosering in fase 3 HYPERION-studie met Sepofarsen voor LCA10
Clermont-Ferrand, France, Wednesday 1 October 2025 – Sepul Bio, an innovative business unit of Théa, dedicated to the advancement of RNA therapies for inherited retinal diseases, has












